1. Home
  2. WWW vs NVAX Comparison

WWW vs NVAX Comparison

Compare WWW & NVAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Wolverine World Wide Inc.

WWW

Wolverine World Wide Inc.

HOLD

Current Price

$20.06

Market Cap

1.5B

ML Signal

HOLD

NVAX

Novavax Inc.

HOLD

Current Price

$11.45

Market Cap

1.5B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
WWW
NVAX
Founded
1883
1987
Country
United States
United States
Employees
N/A
N/A
Industry
Shoe Manufacturing
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.5B
1.5B
IPO Year
2001
1996

Fundamental Metrics

Financial Performance
Metric
WWW
NVAX
Price
$20.06
$11.45
Analyst Decision
Buy
Hold
Analyst Count
9
9
Target Price
$23.25
$11.33
AVG Volume (30 Days)
1.1M
3.9M
Earning Date
05-25-2026
05-20-2026
Dividend Yield
2.00%
N/A
EPS Growth
N/A
309.76
EPS
0.76
2.58
Revenue
$1,755,000,000.00
$1,123,479,000.00
Revenue This Year
$7.35
N/A
Revenue Next Year
$4.83
N/A
P/E Ratio
$26.47
$4.37
Revenue Growth
N/A
64.69
52 Week Low
$9.58
$5.01
52 Week High
$32.80
$11.85

Technical Indicators

Market Signals
Indicator
WWW
NVAX
Relative Strength Index (RSI) 64.47 74.43
Support Level $16.82 $6.34
Resistance Level $20.26 N/A
Average True Range (ATR) 0.78 0.63
MACD 0.14 0.16
Stochastic Oscillator 70.90 85.13

Price Performance

Historical Comparison
WWW
NVAX

About WWW Wolverine World Wide Inc.

Wolverine World Wide Inc is engaged in designing, manufacturing, sourcing, marketing, licensing, and distributing branded footwear, apparel, and accessories. The company's segment includes Active Group; Work Group; Corporate and Other. It generates maximum revenue from the Active Group segment. Active Group segment consists of Merrell footwear and apparel, Saucony footwear and apparel, Sweaty Betty activewear, and Chaco footwear.

About NVAX Novavax Inc.

Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. It works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. The company manages its business as one operating segment, the development and commercialization of vaccines. The company generates maximum revenue from the United States.

Share on Social Networks: